Ari Bousbib is both the Chairman and the CEO of IQVIA Holdings. The corporation isn’t particularly well-known, but it is one of the biggest contract research organizations that can be found in the entire world, which is perhaps unsurprising considering its role in providing assistance with clinical research. Here are 10 things that you may or may not have known about IQVIA Holdings CEO Ari Bousbib:
1. Went to the Ecole Spéciale des Travaux Publics
Bousbib went to a school called the Ecole Spéciale des Travaux Publics. Given its name, it should come as no surprise to learn that it is a French school. Moreover, it is considered to be one of the best engineering schools that can be found in said country, with both construction and project management being considered two of its particular specialties.
2. Went to Columbia University
Later, Bousbib went to Columbia University in New York City as well. There, he studied business administration, with the result that he has a MBA in addition to the graduate degree that he received from the aforementioned engineering school.
3. Was a Consultant At One Point in Time
At one point in time, Bousbib worked at Booz Allen Hamilton, which is a consulting firm that specializes in both IT and management. Bousbib joined up with said consulting firm as an associate in 1987 before managing to become a partner in 1992.
4. Has Worked with a Wide Range of Companies
There are some executives who stay with one or two companies over the entire course of their careers. In contrast, other executives have worked with and will continue to work with a wide range of companies instead. Bousbib is very much a case of the latter, as shown by the fact that he has headed up no fewer than eight different companies.
5. Has Worked in a Wide Range of Positions
On a related note, Bousbib has been in a wide range of positions as well. For example, he has been a Chief Operating Officer, which would be the individual responsible for overseeing the operations. Likewise, he has been a Chief Strategy and Development Officer, which would have focused more upon coming up with a strategy for the company as well as overseeing its new prospects. As such, Bousbib has been very well-prepared for his position at the top.
6. Oversees a Business that Is Very Interested in Data
There are a lot of companies in a lot of sectors that are very interested in collecting data and then analyzing it for useful insight. However, there aren’t a lot of them that can compare to IQVIA Holdings’ interest, seeing as how it is in the business of buying medical data and then selling its insights to medical companies.
7. Oversees a Business that Has Caused Some Privacy Concerns
Unsurprisingly, this means that Bousbib’s company has caused some privacy concerns. After all, personal medical information tends to be pretty sensitive, not least because it can have such a huge impact on a person’s normal life when it is misused in some manner. Unfortunately, IQVIA Holdings is far from being the sole company that is interested in such information, meaning that people who are very sensitive about protecting their personal medical information can expect a lot of frustration in this regard.
8. Came to IQVIA Holdings Via IMS Health
IQVIA Holdings came into existence in October of 2016 through a merger of Quintiles and IMS Health. Bousbib came to the corporation through IMS Health, where he was both the CEO and the Chairman at the time.
9. Oversees a Business that Helps with Clinical Research
One of IQVIA Holdings’s businesses would be helping clinical researchers with their efforts. Examples of its services range from consulting to providing assistance with analysis.
10. Oversees a Business that Specializes in Phases I to IV of Clinical Trials
In particular, IQVIA Holdings under Bousbib’s leadership is said to specialize in Phases I to IV of the clinical trials. For those who are curious, Phase I would be checking a drug’s safety, Phase II would be checking a drug’s effectiveness, Phase III would be a final check of both factors, and then Phase IV would be the post-marketing studies that will continue so long as the drug continues to see use.